粘菌素
头孢他啶/阿维巴坦
医学
替加环素
阿兹屈南
肺炎克雷伯菌
头孢他啶
阿维巴坦
菌血症
微生物学
美罗培南
内科学
重症监护医学
抗生素
铜绿假单胞菌
亚胺培南
抗生素耐药性
生物
大肠杆菌
遗传学
细菌
基因
生物化学
作者
Punit J. Shah,Thuytram Tran,Francis Emelogu,Farheen Tariq
标识
DOI:10.1177/0897190019882262
摘要
A case of a patient with sepsis from a urinary source due to carbapenemase-producing Klebsiella pneumoniae treated with a novel combination of aztreonam, ceftazidime/avibactam, and colistin is described. Summary: An 80-year-old South Asian male presented to the hospital with sepsis from a urinary source. Blood and urine cultures were positive for a carbapenemase-producing K pneumoniae sensitive only to colistin and tigecycline. Novel beta-lactamase inhibitor combinations ceftazidime/avibactam and meropenem/vaborbactam were resistant. Patient was initially on ceftazidime/avibactam and colistin combination followed by tigecycline and colistin with lack of improvement. Metallo-beta-lactamase (MBL)-producing K pneumoniae was suspected based on the sensitivity pattern and history of medical treatment in India. Patient was then initiated on novel combination of ceftazidime/avibactam, aztreonam, and colistin. Patient's white blood cell (WBC) count and fever curve normalized. Unfortunately, the patient failed to recover completely likely because of his multiple comorbidities and declining functional status, resulting in the family's decision to pursue hospice.The combination of ceftazidime/avibactam and aztreonam should be considered as a viable treatment option for patients with infections caused by MBL-producing Enterobacteriaceae.
科研通智能强力驱动
Strongly Powered by AbleSci AI